Literature DB >> 15699742

Mixed hematopoietic chimerism for the simultaneous induction of T and B cell tolerance.

Megan Sykes1, Ichiro Shimizu, Toshiyasu Kawahara.   

Abstract

Nonmyeloablative induction of mixed hematopoietic chimerism provides a strategy for inducing T cell tolerance across allogeneic and xenogeneic barriers. We have utilized alpha1-3Gal transferase (GalT) knockout mice, which, like humans, produce anti-Gal natural antibodies, to investigate the ability of mixed chimerism to tolerize B cells producing antibodies of this important specificity, which limits xenotransplantation by causing hyperacute and delayed xenograft rejection. Mixed allogeneic or xenogeneic chimerism indeed tolerizes both preexisting anti-Gal-producing B cells and those developing de novo after establishment of mixed chimerism, even in presensitized mice. We present evidence that different mechanisms are involved in the tolerization of the preexisting and newly-developing antibody-secreting cells.

Entities:  

Mesh:

Year:  2005        PMID: 15699742     DOI: 10.1097/01.tp.0000153296.80385.e7

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Emerging concepts in haematopoietic cell transplantation.

Authors:  Hao Wei Li; Megan Sykes
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

2.  Xenotransplantation as a model of integrated, multidisciplinary research.

Authors:  Emanuele Cozzi; Erika Bosio; Michela Seveso; Domenico Rubello; Ermanno Ancona
Journal:  Organogenesis       Date:  2009-01       Impact factor: 2.500

3.  Increased levels of anti-non-Gal IgG following pig-to-baboon bone marrow transplantation correlate with failure of engraftment.

Authors:  Fan Liang; Isaac Wamala; Joseph Scalea; Aseda Tena; Taylor Cormack; Shannon Pratts; Raimon Duran-Struuck; Nahel Elias; Martin Hertl; Christene A Huang; David H Sachs
Journal:  Xenotransplantation       Date:  2013-10-29       Impact factor: 3.907

Review 4.  Transplantation tolerance and its outcome during infections and inflammation.

Authors:  Anita S Chong; Maria-Luisa Alegre
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

5.  Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.

Authors:  Nancy M Hardy; Frances Hakim; Seth M Steinberg; Michael Krumlauf; Romana Cvitkovic; Rebecca Babb; Jeanne Odom; Daniel H Fowler; Ronald E Gress; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-16       Impact factor: 5.742

Review 6.  Current status of xenotransplantation and prospects for clinical application.

Authors:  Richard N Pierson; Anthony Dorling; David Ayares; Michael A Rees; Jörg D Seebach; Jay A Fishman; Bernhard J Hering; David K C Cooper
Journal:  Xenotransplantation       Date:  2009 Sep-Oct       Impact factor: 3.907

7.  B-cell tolerance in transplantation: is repertoire remodeling the answer?

Authors:  Ronald F Parsons; Kumar Vivek; Robert R Redfield; Thi-Sau Migone; Michael P Cancro; Ali Naji; Hooman Noorchashm
Journal:  Expert Rev Clin Immunol       Date:  2009-11       Impact factor: 4.473

8.  Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation.

Authors:  Nayoun Kim; Hyunji Lee; Junghoon Shin; Young-Sun Nam; Keon-Il Im; Jung-Yeon Lim; Eun-Sol Lee; Young-Nam Kang; Se-Ho Park; Seok-Goo Cho
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 9.  Improving the safety of tolerance induction: chimerism and cellular co-treatment strategies applied to vascularized composite allografts.

Authors:  Wei-Chao Huang; Jeng-Yee Lin; Christopher Glenn Wallace; Fu-Chan Wei; Shuen-Kuei Liao
Journal:  Clin Dev Immunol       Date:  2012-10-22

10.  Intragraft gene expression profile associated with the induction of tolerance.

Authors:  Tomoko Doki; Michael Mello; Dennis Mock; Jacqueline M Evans; Mary Kearns-Jonker
Journal:  BMC Immunol       Date:  2008-02-11       Impact factor: 3.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.